Although both SGLT2 inhibitors appear to lower the risk of heart failure, we believe that dapagliflozin may have a little higher effect on heart failure reduction than empagliflozin based on data from prior studies and our analyses. The gene discussed is SLC5A2; the disease is heart failure.